Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis 2007;44:79-86.
Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 2003;47:1179-86.
Andes D, vanOgtrop ML, Peng J, et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002;46:3484-9.
Castro-Balado A, Varela-Rey I, Mejuto B, et al. Updated antimicrobial dosing recommendations for obese patients. Antimicrob Agents Chemother 2024;68(5):e0171923. doi: 10.1128/aac.01719-23.
Craig WA. Does the dose matter? Clin Infect Dis 2001;33(suppl 3):S233-7.
Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
Crandon JL, Nicolau DP. Pharmacodynamic approaches to optimizing beta-lactam therapy. Crit Care Clin 2011;27:77-93.
Gilbert DN, Moellering RC, Eliopoulos GM, eds. The Sanford guide to antimicrobial therapy 2012. Sperryville, VA: Antimicrobial Therapy, Inc. 2012.
Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 2011;1:30-5.
Reffert JL, Smith WJ. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Pharmacotherapy 2014;34:845-57 doi:10.1002/phar.1434.
Roberts JA, Lipman F. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009;37:840-51.
Wilby KJ, Nasr ZG, Elazzazy S, et al. A review of clinical outcomes associated with two meropenem dosing strategies. Drugs R D 2017;17:73-8.
Wispelway B. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Infect Dis 2005;40(suppl 7):S439-47.
